Alterity Therapeutics Welcomes New Chief Financial Officer
Alterity Therapeutics (NASDAQ: ATHE), a promising biotechnology company, has announced a significant leadership change. Abby Macnish Niven has joined the firm as its new Chief Financial Officer, effective immediately. This appointment marks a fresh chapter for the company, which is dedicated to developing treatments for neurodegenerative diseases.
Abby Macnish Niven's Background
Ms. Niven brings a wealth of experience in private wealth management, having worked with notable organizations such as ANZ, UBS, and Ord Minett. Her strong financial acumen will undoubtedly support Alterity as it progresses with its innovative programs. As noted by David Stamler, the CEO of Alterity, the company looks forward to the contributions she will make in her new role.
Transition from Phillip Hains
Abby Macnish Niven succeeds Phillip Hains, the former CFO, who played a vital role in the company since December 2023, guiding Alterity through crucial transitional phases. Hains remains with the company as the Company Secretary, ensuring continuity during this change.
Alterity Therapeutics: Innovating for a Better Future
At its core, Alterity Therapeutics specializes in creating innovative solutions for individuals suffering from neurodegenerative conditions. The company is currently focused on its lead asset, ATH434, which shows promising potential in treating various Parkinsonian disorders. This compound is undergoing evaluation in two Phase 2 clinical trials for Multiple System Atrophy, a significant progression in treatment options for patients.
A Commitment to Drug Development
Beyond ATH434, Alterity has developed a robust drug discovery platform. This platform is designed to generate patentable chemical compounds targeting the root causes of neurological diseases. Through extensive research and creative innovation, the company is committed to discovering effective treatments that can change lives.
Corporate Vision and Growth
As the company moves forward, it remains focused on its vision of creating an alternate future for those impacted by neurodegenerative diseases. The leadership of Abby Macnish Niven will play an essential role in steering the company towards achieving its goals while ensuring financial stability and growth.
Contact Information
For those interested in learning more about Alterity, the company provides numerous avenues for communication:
Australia
Hannah Howlett
Email: we-aualteritytherapeutics@we-worldwide.com
Phone: +61 450 648 064
U.S.
Remy Bernarda
Email: remy.bernarda@iradvisory.com
Phone: +1 (415) 203-6386
Frequently Asked Questions
Who is the new Chief Financial Officer of Alterity Therapeutics?
The new CFO is Abby Macnish Niven, appointed to the position recently.
What is the main focus of Alterity Therapeutics?
Alterity focuses on developing treatments for neurodegenerative diseases, particularly with its lead asset, ATH434.
What are the qualifications of Abby Macnish Niven?
Ms. Niven has extensive experience in private wealth management and holds degrees in Commerce and Science.
What is ATH434 being evaluated for?
ATH434 is being tested in Phase 2 clinical trials for its effectiveness in treating Multiple System Atrophy.
How can I contact Alterity Therapeutics?
Individuals can contact the company via email or phone. Contact details for both Australian and U.S. representatives are available in the announcement.
